DOCSLIB.ORG

Appendix PSYCHIATRIC SIDE EFFECTS of MEDICAL DRUGS

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Appendix PSYCHIATRIC SIDE EFFECTS OF MEDICAL DRUGS PSYCHIATRIC SIDE EFFECTS OF MEDICAL DRUGS General Classification Generic Trade Name Psychiatric Side Effects Sulfonamides* Mafenide acetate Sulfamylon General statement regarding Phthelylsulfathiazole sulfonamides: Salicylazosulfapyridine depression Sulfacetamide sodium Sultrin Triple Sulfa psychosis Sulfachlorpyridazine restlessness Sulfadiazine Suladyne irritabili ty Sulfamerazine Sulfameter Sulla Sulfamethazine Sulfamethizole Azotrex Micro sui w Microsul-A (1l w Suladyne *May cause retardation if given Thiosulfil during 3rd trimester, to nursing Thiosulfil Forte mothers, or to children less than Thiosulfil-A Forte 2 months old Uro biotic-250 Sulfamethoxazole Azo Gantanol Bactrim DS Bactrim Gantanol Gantanol DS Septra DS Septra Sulfaphenasole Sulfisoxazole Azo Gantrisin Gantrisin SK-Soxazole Sulfisoxazole Vagilia PSYCHIATRIC SIDE EFFECTS OF MEDICAL DRUGS (Cont.) General Classification Generic Trade Name Psychiatric Side Effects Sulfones Dapsone General statement regarding Sulfoxone sodium sulfones: nervousness insomnia psychosis An thelmin tics Aspidium oleoresin Male Fern Oleoresin Delirium Quinacrime HCl Atabrine HCI Psychosis Tetrachloroethylene Inebriation Antitubercular Agents Cycloserine Seromycin Confusion Lethargy (,) Psychosis 0'1 Ethionamide Trecator-SC Depression .... Isoniazid INH Toxic psychosis Isonicotinic Acid Hydrazine Parasthesia Hyzyd Excitement Laniazid Euphoria Niconyl Nydrazid Teebaconin Rifampin Rifadin Confusion Rimactane Antimalarials Chloroquine HCI Aralen HCI General statement regarding Chloroquine phosphate Aralen Phosphate antimalarials: fatigue lassitude nervousness irri ta bili ty psychosis Amodiaquin HCI Camoquin HCI Spasticity PSYCHIATRIC SIDE EFFECTS OF MEDICAL DRUGS (Cont.) General Classification Generic Trade Name Psychiatric Side Effects Amebicides and Trichomonacides Metronidazole Flagyl Confusion Irritability Depression Insomnia Antineoplastic Agents Fluorouracil Efudex Euphoria 5-Fluorouracil Insomnia 5-FU Irritability Fluoroplex Procarbazine HCI Matulane Depression Psychosis Manic reactions Nervousness 81 Insomnia Nightmares Disorienta tion Delirium Vinblastine sulfate Velban Depression VLB Cardiac Glycosides Acetyldigitoxin Acylanid General statement regarding Deslanoside Cedilanid-D cardiac glycosides: Digitalis glycoside Crystodigin disorientation Digitalis leaf confusion Digitoxin Digitoxin depression Digoxin Digoxin aphasia Lanoxin delirium SK-Digoxin hallucinations Gitalin Gitaligin especially in the elderly Lanatoside C Cedilanid or arteriosclerotic Ouabain Ouabain PSYCHIATRIC SIDE EFFECTS OF MEDICAL DRUGS (Cont.) General Classification Generic Trade Name Psychiatric Side Effects Peripheral Vasodilators Nylidrin HCI Nylidrin Nervousness Arlidin Antihypertensive Agents Rauwolfia Alkaloids Alseroxylon General statement regarding Deserpidine Enduronyl RauwolfIa alkaloids: Harmonyl nightmares Oreticyl depression (to point of RauwolfIa serpentina Raudixin suicide attempt) Rauzide Rare: nervousness, paradoxical Rauwolfia Serpentine anxiety, decreased libido, Rescinnamine Moderil Parkinson-like syndrome U) Reserpine Bu tiserpazide-25/50 ~ Prestabs Demi-Regroton Diupres Diutensen-R Dralserp Exna-R Hydromox R Hydropres Hydrotensin-50 Hydrotensin-Plus Metatensin Naquival Ran-Sed Regroton Renese-R Reserpine Ruhexatal with reserpine SK-Reserpine PSYCHIATRIC SIDE EFFECTS OF MEDICAL DRUGS (Cont.) General Classification Generic Trade Name Psychiatric Side Effects Rauwolfia Alkaloids (Cont.) Reserpine (Cont.) Salutensin Sandril Ser-Ap-Es Serpasil Serpasil-Apresoline Serpasil-Esidrix Syrosingopine Singoserp-Esidrix Ganglionic Blocking Agents Mecamylamine HCI General statement regarding Pentolinium tartrate ganglionic blocking agents: Trimethaphan camsylate Arfonad tremor confusion c,.) Sympathetic Nervous System ~ Depressants Guanethidine sulfate Ismelin Sulfate Depression Methyldopate HQ Aldomet HCl Parkinsonism Diminished cognition Choreoathetotic movements Nightmares Depression Psychosis Methyldopa Aldomet Parkinsonism Aldoc1or Diminished cognition Aldoril Choreoathetotic movements Nightmares Depression Psychosis Agents that Act Directly on Vascular Smooth Muscle Hydralazine HQ Apresazide Depression Apresoline HQ Disorientation Apresoline-Esidrix Anxiety PSYCHIATRIC SIDE EFFECTS OF MEDICAL DRUGS (Cont.) General aassification Generic Trade Name Psychiatric Side Effects Agents that Act Directly on Vascular Smooth Muscle (Cont.) Hydralazine HCI (Cont.) Dralserp Dralzine Hydralazine HO Hydrotensin-Plus Ser-Ap-Es Serpasil-Apresoline Unipres Antiarrhythmic Agents Lidocaine HCI Anestacon Transient excitement LTA 11 Depression CAl Lidocaine HO Restlessness ~ Lidosporin Euphoria Xylocaine HO Apprehension Propranolol HCI Inderal Hallucinations Insomnia Incoordination Hypocholesterolemic and Antilipemic Agents Nicotinic acid Cerebro-Nicin Nervousness Diacin Panic reactions Lipo-Nicin Menic Niac Niacin Nicalex Nicobid Nicocap Nico-400 Nicolar Nico-Metrazol PSYCHIATRIC SIDE EFFECTS OF MEDICAL DRUGS (Cont.) General Classification Generic Trade Name Psychiatric Side Effects Hypocholesterolemic and Antilipemic Agents (Cont.) Nicotinic acid (Cont.) Nico-Span Nicotinex Elixir Nicozol Progiatric Ragus Tega-Span Tinic Wampocap Dextrothyroxine sodium Choloxin Insomnia Nervousness Changes in libido (> or <) (0) Bizarre subjective complaints g Barbiturates Amobarbital Amesec General statement regarding Amy tal barbiturates: Dexamyl excitement Ectasule euphoria Amobarbital sodium Amytal Sodium restlessness Tuinal delirium Aprobarbital A.P.B. psychological dependence Alurate Elixir nervousness Alurate Elixir Verdum Butabarbital Broncomar Butabarbital Sodium Elixir Butiserpazide-2S/S0 Cystospaz-SR Dolonil Quibron Plus Sedapap-lO Sidonna Tedral-25 PSYCHIATRIC SIDE EFFECTS OF MEDICAL DRUGS (Cont.) General Oassifieation Generic Trade Name Psychiatric Side Effects Barbiturates (Cont.) Butabarbital sodium Butieaps Butisol Dularin-TH Gaysal Minotal Phrenilin Hexobarbital Mephobarbital Mebaral Metharbital Gemonil Methhexital sodium Pentobarbital Erne-Nil Inserts Emesert Inserts Matropinal Matropinal Forte ~ Nembutal Elixir Pentobarbital Sodium Phenobarbital A.P.B. Antroeol Areo-Lase Plus Belap Bentyl with Phenobarbital Bronkolixir Bronkotabs Bronkotabs-Hafs Cantil with Phenobarbital Cardilate-P Donphen Eskabarb Gaysal Gustase-Plus Isordil PSYCIDATRIC SIDE EFFECTS OF MEDICAL DRUGS (Cont.) General Classification Generic Trade Name Psychiatric Side Effects Barbiturates (Cont.) Phenobarbital (Cont.) Levsin/Phenobarbital Levsinex/Phenobarbital Lufyllin-EPG Luminal Matropinal Mundrane GG Oxoids PaminePB Peritrate with Phenobarbital Phazyme-PB Phenobarbital Pro-Banthine with Phenobarbital c.l Proval ~ Quadrinal Robinul with Phenobarbital SK-Phenobarbital Solfoton Trasentine with Phenobarbital Valpin Verequad Phenobarbital sodium Luminal Sodium Secobarbital Antora-B Secobarbital Seconal Elixir Secobarbital sodium Seconal Sodium Talbutal Lotusate Thiamylal sodium Surital Sodium Thiopental sodium Pentothal Sodium PSYCHIATRIC SIDE EFFECTS OF MEDICAL DRUGS (Cont.) General Classifica tion Generic Trade Name Psychiatric Side Effects Nonbarbiturate sedatives and hypnotics Bromide salts Sodium Bromide psychosis Potassium Depression Ammonium Bromide salts, mixed Neurosine Depression Bromide psychosis Bromisovalum Bromural Bromide psychosis Chloral hydrate Aquachloral Paranoid reactions Chloral Hydrate Chloral delirium Cohydrate Felsules Kessodrate Somnambulism (,) Lycoral I\)en Noctec Oradrate Rectules SK-Chloral Hydrate Somnos Ethinamate Valmid Paradoxical excitement in children Glutethimide Doriden Psychosis Glutethimide, NF Confusion Delirium Hallucinations Methyprylon Noludar Paradoxical excitement Confusion PSYCHIATRIC SIDE EFFECTS OF MEDICAL DRUGS (Cont.) General Classification Generic Trade Name Psychiatric Side Effects Anticonvulsants Hydantoins DiphenyJhydan toin Dihycon General statement regarding Dilantin hydantoins: DPH hallucinations Ekko delusions Phenytoin extrapyramidal reactions Toin Unicelles Diphenylhydantoin sodium Dilantin Sodium Kessodanten Phenytoin Sodium Ethotoin Peganone ffi Mephenytoin Mesantoin Confusion Psychosis Irritability Depression Succinimides Ethosuximide Zarontin General statement regarding Phensuximide Milontin succinimides: nervousness apathy euphoria depression Methsuximide Celontin personality change confusion severe depression Miscellaneous Phenacemide Phenurone Psychosis with suicidal tendencies Depression Aggressiveness PSYCIUA TRIC SIDE EFFECTS OF MEDICAL DRUGS (Cont.) General C1assification Generic Trade Name Psychiatric Side Effects MisceUaneous (Cont.) Primidone Mysoline Irritability Hyperexcitability (particularly in children) Narcotic analgesics Morphine and Congeners Codeine Calcidrine Syrup General statement regarding Empracet with Codeine morphine and congeners: Promethazine HCl mental clouding Expectorant with Codeine euphoria Pyribenzamine Expectorant excitement with Codeine &; Ephedrine restlessness SK-APAP with Codeine delirium I Codeine phosphate APC with Codeine insomnia Actifed-C Ascodeen-30 Ascriptin with Codeine Bancap with Codeine Capital with Codeine Chlor-Trimeton Expectorant with Codeine Codalan CodimalPH Colrex Compound Dimetane Expectorant-DC Empirin Compound with Codeine Emprazil-C Fiorinal with Codeine Isoclor Expectorant Novahistine DH Novahistine Expectorant PSYCHIATRIC SIDE EFFECTS OF MEDICAL DRUGS (Cont.) General Oassification Generic Trade Name Psychiatric Side Effects Morphine and Congeners (Cont.) Codeine
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 Mckay Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 Mckay Et Al

    US 20080317805A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 McKay et al. (43) Pub. Date: Dec. 25, 2008 (54) LOCALLY ADMINISTRATED LOW DOSES Publication Classification OF CORTICOSTEROIDS (51) Int. Cl. A6II 3/566 (2006.01) (76) Inventors: William F. McKay, Memphis, TN A6II 3/56 (2006.01) (US); John Myers Zanella, A6IR 9/00 (2006.01) Cordova, TN (US); Christopher M. A6IP 25/04 (2006.01) Hobot, Tonka Bay, MN (US) (52) U.S. Cl. .......... 424/422:514/169; 514/179; 514/180 (57) ABSTRACT Correspondence Address: This invention provides for using a locally delivered low dose Medtronic Spinal and Biologics of a corticosteroid to treat pain caused by any inflammatory Attn: Noreen Johnson - IP Legal Department disease including sciatica, herniated disc, Stenosis, mylopa 2600 Sofamor Danek Drive thy, low back pain, facet pain, osteoarthritis, rheumatoid Memphis, TN38132 (US) arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural (21) Appl. No.: 11/765,040 space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug (22) Filed: Jun. 19, 2007 depot. E Day 7 8 Day 14 El Day 21 3OO 2OO OO OO Control Dexamethasone DexamethasOne Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr 0.0032ng/hr 0.016 ng/hr 0.08 ng/hr Patent Application Publication Dec. 25, 2008 Sheet 1 of 2 US 2008/0317805 A1 900 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 80.0 - 7OO – 6OO - 5OO - E Day 7 EDay 14 40.0 - : El Day 21 2OO - OO = OO – Dexamethasone Dexamethasone Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr O.OO32ng/hr O.016 ng/hr 0.08 nghr Patent Application Publication Dec.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation

    Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation

    www.sciencemag.org/cgi/content/full/327/5963/348/DC1 Supporting Online Material for Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation Jason Rihel,* David A. Prober, Anthony Arvanites, Kelvin Lam, Steven Zimmerman, Sumin Jang, Stephen J. Haggarty, David Kokel, Lee L. Rubin, Randall T. Peterson, Alexander F. Schier* *To whom correspondence should be addressed. E-mail: [email protected] (A.F.S.); [email protected] (J.R.) Published 15 January 2010, Science 327, 348 (2010) DOI: 10.1126/science.1183090 This PDF file includes: Materials and Methods SOM Text Figs. S1 to S18 Table S1 References Supporting Online Material Table of Contents Materials and Methods, pages 2-4 Supplemental Text 1-7, pages 5-10 Text 1. Psychotropic Drug Discovery, page 5 Text 2. Dose, pages 5-6 Text 3. Therapeutic Classes of Drugs Induce Correlated Behaviors, page 6 Text 4. Polypharmacology, pages 6-7 Text 5. Pharmacological Conservation, pages 7-9 Text 6. Non-overlapping Regulation of Rest/Wake States, page 9 Text 7. High Throughput Behavioral Screening in Practice, page 10 Supplemental Figure Legends, pages 11-14 Figure S1. Expanded hierarchical clustering analysis, pages 15-18 Figure S2. Hierarchical and k-means clustering yield similar cluster architectures, page 19 Figure S3. Expanded k-means clustergram, pages 20-23 Figure S4. Behavioral fingerprints are stable across a range of doses, page 24 Figure S5. Compounds that share biological targets have highly correlated behavioral fingerprints, page 25 Figure S6. Examples of compounds that share biological targets and/or structural similarity that give similar behavioral profiles, page 26 Figure S7.
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E

    A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E

    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
  • Wo 2010/075090 A2

    Wo 2010/075090 A2

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
  • CANVAS Trial)

    CANVAS Trial)

    Effectiveness research with Real World Data to support FDA’s regulatory decision making 1. RCT Details This section provides a high-level overview of the RCT that the described real-world evidence study is trying to replicate as closely as possible given the remaining limitations inherent in the healthcare databases. 1.1 Title Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS trial) 1.2 Intended aim(s) To compare canagliflozin to placebo on cardiovascular (CV) events including CV death, heart attack, and stroke in patients with type 2 diabetes mellitus (T2DM), whose diabetes is not well controlled at the beginning of the study and who have a history of CV events or have a high risk for CV events. 1.3 Primary endpoint for replication and RCT finding Major Adverse Cardiovascular Events, Including CV Death, Nonfatal Myocardial Infarction (MI), and Nonfatal Stroke 1.4 Required power for primary endpoint and noninferiority margin (if applicable) With 688 cardiovascular safety events recorded across the trials, there would be at least 90% power, at an alpha level of 0.05, to exclude an upper margin of the 95% confidence interval for the hazard ratio of 1.3. 1.5 Primary trial estimate targeted for replication HR = 0.86 (95% CI 0.75–0.97) comparing canagliflozin to placebo (Neal et al., 2017) 2. Person responsible for implementation of replication in Aetion Ajinkya Pawar, Ph.D. implemented the study design in the Aetion Evidence Platform. S/he is not responsible for the validity of the design and analytic choices. All implementation steps are recorded and the implementation history is archived in the platform.
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
  • Prohibited Substances List

    Prohibited Substances List

    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
  • A2) United States Patent (0) Patent No.: US 9,078,919 B2 Olsonet Al

    A2) United States Patent (0) Patent No.: US 9,078,919 B2 Olsonet Al

    US009078919B2 a2) United States Patent (0) Patent No.: US 9,078,919 B2 Olsonet al. (45) Date of Patent: *Jul. 14, 2015 (54) MICRO-RNAS OF THE MIR-15 FAMILY 2005/0182011 Al 8/2005 Olson etal. MODULATE CARDIOMYOCYTE SURVIVAL 2006/0058266 Al 3/2006 Manoharan etal. AND CARDIAC REPAIR 2006/0105360 Al 5/2006 Croce etal. 2006/0165659 Al 7/2006 Croceet al. 2006/0185027 Al 8/2006 Bartelet al. (71) Applicant: The Board of Regents, The University 2006/0189557 Al 8/2006 Slack et al. of Texas System, Austin, TX (US) 2006/0247193 Al 11/2006 Taira et al. 2006/0252722 Al 11/2006 Lollo et al. (72) Inventors: Eric N. Olson, Dallas, TX (US); Eva 2007/0026403 Al 2/2007 Hatzigeorgiouetal. 2007/0054287 Al 3/2007 Bloch van Rooij, Utrecht (NL) 2007/0213292 Al 9/2007 Stoffel et al. 2007/0259827 Al 11/2007 Aronin et al. (73) Assignee: The Board of Regents, the University 2007/0287179 Al 12/2007 Tuschletal. of Texas System, Austin, TX (US) 2007/0292878 Al 12/2007 Raymond. 2008/0050744 Al 2/2008 Brownetal. (*) Notice: Subject to any disclaimer, the term of this 2008/0176766 Al 7/2008 Brownetal. 2008/0220423 Al 9/2008 Molleret al. patent is extended or adjusted under 35 2009/0053718 Al 2/2009 Naguibnevaetal. U.S.C. 154(b) by 0 days. 2009/0092980 Al 4/2009 Arenzet al. 2009/0131356 Al 5/2009 Baderet al. This patent is subject to a terminal dis- 2009/0176723 Al 7/2009 Brownetal. claimer. 2009/0214477 Al 8/2009 Betzet al.
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130210835A1 (19) United States (12) Patent Application Publication (10) Pub. N0.2 US 2013/0210835 A1 Mitchell (43) Pub. Date: Aug. 15, 2013 (54) PHARMACEUTICAL COMPOSITIONS Publication Classi?cation (75) Inventor: Odes W. Mitchell; Arlington, TX (U S) (51) Int. Cl. A61K31/137 (2006.01) _ A611; 31/4402 (2006.01) (73) Ass1gnee: GM PHARMACEUTICAL, INC, A61K 31/485 (200601) Arhngton, TX (Us) A611; 31/09 (2006.01) _ A611; 31/495 (2006.01) (21) App1.No.. 13/703,584 A61K31/505 (200601) 22 PCT P1 d: J .13 2011 (52) us Cl ( ) 1e “n ’ CPC ........... .. A611; 31/137 (2013.01); A611;31/495 (86) PCT NO. PCT/“11,4031 (2013.01); A611;31/505 (2013.01); A611; 31/485 (2013.01); A611; 31/09 (2013.01); § 371 (0)0). A611;31/4402 (2013.01) (2), (4) Date: Feb- 2, 2013 USPC .... .. 514/255.04; 564/355; 514/653; 544/396; 544/332; 514/275; 546/74; 514/289; 514/282; Related US. Application Data 514657; 514652 (60) Provisional application No. 61/354,061; ?led on Jun. (57) ABSTRACT 11; 2010; provisional application No. 61/354,057; A composition of an antitussive; a decongestant; or an anti ?led on Jun. 11; 2010; provisional application No. histamine to treat respiratory and oral pharyngeal congestion 61/354,053; ?led on Jun. 11,2010. and related symptoms in a patient. US 2013/0210835 A1 Aug. 15,2013 PHARMACEUTICAL COMPOSITIONS mucus build-up to clear congestion in the air passages. Symp toms due to allergies or allergens are often treated With an CROSS-REFERENCES TO RELATED antihistamine.
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01